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Abstract
Nitric oxide synthase-3 (NOS3) has recently been shown to promote endothelial-to-mesenchymal transition (EndMT) in the
developing atrioventricular (AV) canal. The present study was aimed to investigate the role of NOS3 in embryonic
development of AV valves. We hypothesized that NOS3 promotes embryonic development of AV valves via EndMT. To test
this hypothesis, morphological and functional analysis of AV valves were performed in wild-type (WT) and NOS32/2 mice at
postnatal day 0. Our data show that the overall size and length of mitral and tricuspid valves were decreased in NOS32/2
compared with WT mice. Echocardiographic assessment showed significant regurgitation of mitral and tricuspid valves
during systole in NOS32/2 mice. These phenotypes were all rescued by cardiac specific NOS3 overexpression. To assess
EndMT, immunostaining of Snail1 was performed in the embryonic heart. Both total mesenchymal and Snail1+ cells in the
AV cushion were decreased in NOS32/2 compared with WT mice at E10.5 and E12.5, which was completely restored by
cardiac specific NOS3 overexpression. In cultured embryonic hearts, NOS3 promoted transforming growth factor (TGFb),
bone morphogenetic protein (BMP2) and Snail1expression through cGMP. Furthermore, mesenchymal cell formation and
migration from cultured AV cushion explants were decreased in the NOS32/2 compared with WT mice. We conclude that
NOS3 promotes AV valve formation during embryonic heart development and deficiency in NOS3 results in AV valve
insufficiency.
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are still detectable and this level of NOS3 expression in the
myocardium remains into adulthood [9].
The atrioventricular (AV) valve development starts at E9 with
the formation of endocardial cushions. A subpopulation of
endocardial cells of the endocardial cushion undergoes endothelial-to-mesenchymal transition (EndMT) and provides the primary
cell source for the development of AV valves [10]. Proliferation of
the mesenchymal cells and matrix deposition extend the cushions
into the cardiac lumen and form primordia of each distinct valve.
This is followed by elongation and remodeling of the valve
primordia, which leads to the gradual formation of valves by E15
[11]. The valves continue to grow and remodel throughout heart
development and well after birth [12–14]. EndMT is a crucial
process for proper formation of AV valves [15]. Transforming
growth factor (TGFb), bone morphogenetic protein (BMP)-2, and
Snail1 have been shown to promote EndMT and valve formation
[16]. We have shown that NOS3 is important for embryonic heart
development [17]. Deficiency in NOS3 leads to congenital septal
defect, bicuspid aortic valves and coronary artery malformation
[18–20]. In addition, Notch-dependent NOS3 activation has been
shown to promote EndMT in the developing AV canal from E9 to
E11.5 via activation of the PI3-kinase/Akt pathway [21]. The
temporal expression pattern of NOS3 peaks during AV valve
formation along with its role in EndMT, suggesting that NOS3

Introduction
Valvular heart disease is a significant health problem and
contributes to more than 44,000 deaths in United States annually
[1]. The causes of valvular heart disease include congenital
malformation and rheumatic disease which is secondary to
bacterial infection. Congenital valve disease affects about 2% of
the general population [2,3]. The disease may manifest as valvular
stenosis, an obstruction of outflow, or as regurgitation, a defective
closure resulting in backward flow. Congenital valve malformations tend to cluster in families among both close and distant
relatives, suggesting a genetic component of this disease [4,5].
However, molecular mechanisms responsible for congenital valve
disease are still not fully understood.
Nitric oxide synthase (NOS) enzymes convert L-arginine to Lcitrulline and produce nitric oxide (NO), a signaling molecule
involved in a wide range of physiological processes including
apoptosis, angiogenesis, cell proliferation and differentiation [6–8].
Three distinct isoforms of NOS has been identified: neuronal
NOS (NOS1), inducible NOS (NOS2) and endothelial NOS
(NOS3). The expression of NOS3 starts around E9.5 during early
mouse embryonic heart development [9]. This expression remains
high until E13.5. By E14.5, the levels of NOS3 expression
decrease in both atria and ventricles. After E19.5 low NOS3 levels
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NOS3 overexpression completely rescued these abnormalities in
the NOS32/2 animals (Figure 2A–D, 3A–D).
To assess cardiac function, ejection fraction and fractional
shortening were determined. Our data showed that ejection
fraction and fractional shortening of both left and right ventricles
were significantly decreased in NOS32/2 compared with NOS3+/
+
mice (P,0.05, Figure 4A–D). Cardiomyocyte-specific NOS3
overexpression in NOS32/2 mice restored ejection fraction and
fractional shortening in both left and right ventricles to levels
comparable to the NOS3+/+ mice (Figure 4A–D). Additionally, we
assessed the E/A ratio of the AV valves, which represents diastolic
function or the ability of the blood to flow from the atria to the
ventricles. E represents the passive filling of blood from atria to
ventricles, whereas A represents the active contraction of the atria
that pumps blood to the ventricles. Our results showed that no
significant difference was observed between all groups in E/A
ratios or the ability of the blood to flow from the atria to the
ventricles (Figure 4E–F). Lastly, as a consequence of AV valve
regurgitation, the size of atria would increase due to the backward
flow from the ventricles. As expected, the size of both left and right
atrium was significantly increased in the NOS32/2 compared
with NOS3+/+ mice, which was restored in NOS3Tg;NOS32/2
mice at P0 (P,0.05, Figure 4G–H).

may participate in the development of the AV valves. However,
the role of NOS3 in the formation and functioning of AV valves
has not been studied. In the present study, we hypothesized that
NOS3 promotes embryonic development of AV valves via
EndMT. To test this hypothesis, morphological changes and
functional competence of AV valves were studied in wild-type
(NOS3+/+), NOS32/2 and cardiac specific NOS3 overexpressing
(NOS3Tg) mice. Expression of human NOS3, driven by the bmyosin heavy chain promoter, was detected only in the embryonic
heart of NOS3Tg mice. The NOS3Tg mice were then crossed with
NOS32/2 to create the NOS3Tg;NOS32/2 mouse, an animal
that lacks NOS3 in all organs except the heart during embryogenesis. Furthermore, the role of NOS3 in endocardial EndMT
and signaling pathway critical to AV valve development was also
examined. Our study demonstrated that NOS3 promotes endocardial EndMT and embryonic AV valve development.

Results
Deficiency in NOS3 Impairs AV Valve Formation
Trichrome staining of mitral and tricuspid valves in NOS3+/+,
NOS32/2, NOS3Tg and NOS3Tg;NOS32/2 mice at P0 is shown
in Figure 1A–D, G–J. In NOS32/2 hearts, AV valves were much
smaller than those of other genotypes. The size of proximal (hinge)
and distal aspects of the valve leaflets was measured as illustrated
in Figure 1M. Quantitative analysis of mitral and tricuspid valves
show that the size and length of the proximal and distal leaflets
were significantly smaller in the NOS32/2 compared with
NOS3+/+ hearts (P,0.05, Figure 1E–F, K–L, S1F, S2F).
Cardiomyocyte-specific NOS3 overexpression (NOS3Tg;NOS32/
2
) completely rescued these defects in the NOS32/2 mice
(P,0.05, Figure 1E–F, 1K–L, S1F, S2F). To investigate whether
the valvular defect in the NOS32/2 animals is due to premature
maturation, cell density in the valves was measured [12–14]. Our
data showed that there was no significant difference in cell density
in mitral and tricuspid valves among all groups at P0 (Figure S1G
and S2G). Furthermore, the decrease in valve length was evident
as early as E15.5 in both mitral and tricuspid valves (Figure S3A–
B). These data supports a developmental defect rather than
premature maturation of the AV valves in NOS32/2 mice.
The volume of the mitral and tricuspid valves was determined
through 3D reconstructions (Figure S1A–E and S2A–E). The
normal mitral valve of NOS3+/+ mice had 2 distinct leaflets. The
overall volume of the mitral valve was significantly smaller in
NOS32/2 compared with NOS3+/+ mice, which was restored by
cardiomyocyte-specific NOS3 overexpression in the NOS3Tg;NOS32/2 mice (P,0.01, Figure S1A–E). The tricuspid valve of
NOS3+/+ mice had 3 distinct leaflets. Similar to the findings in the
mitral valve, the overall volume of tricuspid valve was significantly
decreased in NOS32/2 compared with NOS3+/+ mice, which was
completely rescued by cardiomyocyte-specific NOS3 overexpression in the NOS3Tg;NOS32/2 mice (P,0.01, Figure S2A–E).

Total Mesenchymal and Snail1+ Cells are Decreased in
the Endocardial Cushion of NOS32/2 Mice
Snail1 is a zinc finger transcriptional repressor, which inhibits
adhesion molecule E-cadherin expression and induces EndMT
during embryonic development [22,23]. Therefore, Snail1 is an
excellent marker of mesenchymal cells in the AV cushion. To
further elucidate the role of NOS3 in early AV valve formation,
immunostaining of Snail1 was performed and Snail1+ mesenchymal cells were quantified at E10.5 and E12.5. Our data showed
that while there were no significant changes in the overall size and
volume of the AV endocardial cushion at E10.5 and E12.5
(Figure 5D, G), both total mesenchymal and Snail1 positive cells
(brown staining in histology) in the endocardial cushion were
significantly decreased in NOS32/2 compared with NOS3+/+
hearts (P,0.05, Figure 5A–C, E, F). Three-dimensional reconstruction of Snail1 expression (labeled in red) in the NOS3+/+ mice
showed Snail1 completely covered the outer part of the
endocardial cushion, which represents cells that are actively
undergoing EndMT (Figure 5A). However, in the NOS32/2 mice,
only limited parts of the endocardial cushion were Snail1 positive,
indicating the EndMT process is impaired in the NOS32/2 mice.
The number of Snail1 positive and total mesenchymal cells was
completely restored by cardiac specific NOS3 overexpression
(P,0.05, Figure 5A–C, E, F).

cGMP Signaling is Decreased in NOS32/2 Hearts
cGMP, a downstream signaling molecule of NOS3, was
significantly decreased in the NOS32/2 compared with NOS3+/
+
hearts at P0 (P,0.05, Figure 6A). Cardiac specific NOS3
overexpression in NOS32/2 mice increased myocardial cGMP to
similar levels of NOS3+/+ mice (Figure 6A). To elucidate the
precise role of NOS3 in regulating Snail1 expression, ex vivo E12.5
heart cultures were employed. The TGFb and BMP family
proteins are critical to AV valve development [15,16]. Treatment
with ODQ, a soluble guanylyl cyclase inhibitor significantly
decreased TGFb1, BMP2 and Snail1 mRNA expression in the
NOS3+/+ hearts (P,0.05, Figure 6B–D). Conversely, NOS32/2
hearts treated with 8-Bromo-cGMP, a cGMP analog showed a
significant increase in TGFb1, BMP2 and Snail1 mRNA levels
(P,0.05, Figure 6B–D). These data suggest that NOS3 regulates

Regurgitation of AV Valves in NOS32/2 Mice
In order to investigate the functional significance of AV
malformation in NOS32/2 mice, echocardiographic imaging
analysis was performed on NOS3+/+, NOS32/2, NOS3Tg and
NOS3Tg;NOS32/2 mice at P0 live animals. Color flow Doppler
recordings showed backflow of mitral (Figure 2A) and tricuspid
(Figure 3A) valves in NOS32/2 mice. Using pulsed-wave Doppler,
the backflow velocity and duration were quantified. The velocity
and duration of backflow in mitral (Figure 2B–D) and tricuspid
valves (Figure 3B–D) were significantly increased in NOS32/2
compared with NOS3+/+ mice (P,0.05). Cardiomyocyte-specific
PLOS ONE | www.plosone.org
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Figure 1. Malformation of mitral and tricuspid valves in NOS32/2 mice, which are rescued by cardiomyocyte-specific NOS3
overexpression (NOS3Tg;NOS32/2). Representative tissue sections with Masson’s trichrome staining of mitral (A–D) and tricuspid (G–J) valves in
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WT, NOS32/2, NOS3Tg and NOS3Tg;NOS32/2 mice at P0. (E and F) Quantification of mitral valve size. (K and L) Quantification of tricuspid valve size.
Anterior and posterior leaflets represent the valve leaflet closer to the septum and ventricular free wall, respectively. (M) Valve size was measured at
the proximal (hinge) and distal aspects of the leaflets. White arrows represent proximal and distal measurements. Black arrow points to the hinge of
the valve. Scale bar = 60 mm. Data are mean 6 SEM from 5–8 mice per group. *P,0.05 vs. WT (NOS3+/+), {P,0.05 vs. NOS32/2 mice.
doi:10.1371/journal.pone.0077611.g001

options other than invasive open-chest surgery. The molecular
mechanisms underlying this disease are still largely unknown. The
present study on the role of NOS3 in AV valve formation provides
a possible mechanistic explanation to AV valve insufficiency.
Snail1, a zinc finger transcriptional repressor, is critical to
induction of EndMT during embryonic development [22]. Snail1
knockout mice have defects in mesoderm formation and die
around E7.5 [29]. In addition, deletion of Snai1 specifically in the
epiblast results in death by E9.5 due to multiple vascular defects
and increased apoptosis [30]. To investigate the role of NOS3 in
early AV valve formation, in vivo Snail1 expression and ex vivo
endocardial EndMT were assessed. Our results showed that both
total mesenchymal and Snail1 positive cells in the endocardial
cushion were significantly decreased in NOS32/2 compared with
NOS3+/+ hearts at E10.5 and E12.5 (Figure 5). In addition, the
total number of mesenchymal cells from E10.5 endocardial
cushion cultures was significantly decreased in NOS32/2 explants
(Figure 7A, B). These data show a reduction of endocardial
EndMT in the NOS32/2 mice leading to malformation of mitral
and tricuspid valves.
TGFb is expressed at high levels in AV mesenchyme during
cushion formation and critical to EndMT and AV valve
development [31]. Blockade of TGFb2 by neutralizing antibody
inhibits EndMT in mouse heart explants and TGFb2 knockout
mice show valvular defects [32,33]. BMP2 is also important for
AV cushion EndMT. Nkx2.5 mediated deletion of BMP2 reduced
AV cushion formation and cellularity [34]. A classic pathway by
which NO mediates its biological function is through cGMPdependent protein kinase G (PKG) signaling [35]. In this regard,
NO has been shown to upregulate TGFb1 and BMP2 via PKG
dependent pathway [36–38]. In order to study the molecular
mechanism by which NOS3 promotes endocardial EndMT and
AV valve development, ex vivo E12.5 heart cultures were carried
out to investigate the role of NO/cGMP signaling in the
expression of TGFb1, BMP2 and Snail1. We showed that
inhibition of guanylate cyclase decreased TGFb1, BMP2 and
Snail1 expression in the NOS3+/+ hearts while treatment with 8Bromo-cGMP increased TGFb, BMP2 and Snail1 mRNA levels
in the NOS32/2 hearts. These findings indicate that NOS3 acts as
an upstream regulator of TGFb1, BMP2 and Snail1 through a
cGMP-dependent pathway. Notably, TGFb1 and BMP are able to
induce Snail1expression [15,16]. To this end, we showed that
recombinant TGFb treatment significantly increased Snail1
expression in NOS3+/+ and NOS32/2 hearts. Taken together,
our data suggest that cGMP production from NOS3 upregulates
TGFb and BMP2, and promotes Snail1 expression and EndMT,
leading to normal AV valve development (Figure 7C).
In summary, endocardial EndMT, an important process
required for valvulogenesis is impaired in NOS32/2 mice at
E10.5 and E12.5, leading to malformation, insufficiency and
regurgitation of AV valves at P0. We anticipate that these new
insights into the mechanisms of AV valve development may lead
to therapeutic strategies in the prevention and possibly treatment
of AV valve insufficiency.

the expression of TGFb1, BMP2 and Snail1 through a cGMPdependent pathway. To investigate if TGFb regulates Snail1
signalling, recombinant TGFb was used to treat NOS3+/+ and
NOS32/2 hearts. Our data showed that recombinant TGFb
protein treatment significantly increased Snail1 expression in
NOS3+/+ and NOS32/2 hearts (P,0.05, Figure 6E).

EndMT is Impaired in NOS32/2 Endocardial Cushions
To further confirm the role of NOS3 in endocardial EndMT,
endocardial cushions from E10.5 embryos were dissected and
cultured on collagen type I gel. Collagen type I gel was chosen to
simulate the in vivo conditions of the cardiac jelly, which the
mesenchymal cells migrate into. After 2 days of culture, cells that
underwent EndMT exhibited spindle-like morphology and
migrated from the endocardial cushion into the collagen gel.
Results showed the total number of mesenchymal cells was
significantly decreased in NOS32/2 compared to NOS3+/+
explants (P,0.05, Figure 7A–B), suggesting NOS3 promotes
endocardial EndMT.

Discussion
The present study was carried out to examine the role of NOS3
in AV valve formation. We demonstrated for the first time that
deficiency in NOS3 leads congenital AV valve defects. Additionally, lack of NOS3 also impairs endocardial EndMT. Furthermore, we showed that cardiomyocyte-specific NOS3 overexpression mice completely rescued these defects in NOS32/2 mice. In
order to assess the functional significance of these defects,
echocardiography was carried out on P0 live animals. Our data
showed severe regurgitation of both mitral and tricuspid valves in
the NOS32/2 mice. This phenotype was accompanied by reduced
ejection fraction and fractional shortening and increased atrial
size. Moreover, cardiomyocyte-specific NOS3 overexpression
completely rescued these phenotypes. Our study suggests that
NOS3 promotes endocardial EndMT and embryonic development of AV valves (Figure 7C).
The main function of AV valves is to direct blood flow from
atria to ventricles, and from ventricles to the pulmonary and
systemic circulations. Clinically, AV valve regurgitation can
present in various forms depending on etiology and severity
[23]. In the case of acute AV valve regurgitation, heart failure and
cardiogenic shock may occur leading to death as a result of
backflow from the ventricles and volume overload [24,25]. Severe
AV valve regurgitation, cardiac dysfunction and increases in atrial
size were observed in NOS32/2 mice. These phenotypes highly
resemble congenital AV valve insufficiency, a clinical condition
with infants born with shortened or a complete lack of AV valves
[26,27]. Mitral valve insufficiency is often associated with other
cardiac defects such as atrial septal defects (ASD), ventricular
septal defects (VSD), aortic valve insufficiency and tricuspid valve
insufficiency [28]. Tricuspid valve insufficiency, also known as
tricuspid valve regurgitation, is also associated with congenital
cardiac defects such as VSD and mitral valve regurgitation [26].
These accompanying cardiac defects are very similar to phenotypes seen in the NOS32/2 mice providing an excellent animal
model to study AV insufficiency [18,19]. Clinically, AV valve
insufficiency is a serious congenital heart disease with very limited
PLOS ONE | www.plosone.org
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Figure 2. Regurgitation of mitral valve in NOS32/2 mice at P0. Backflow of mitral valves was determined by color (A) and pulsed-wave (B)
Doppler echocardiography. Backflow during systole is indicated by arrows. WT mice had no backflow in mitral valves. However, NOS32/2 mice
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showed significant mitral valve backflow. (C–D) Quantification of mitral valve regurgitation. Significant regurgitation was observed in NOS32/2 mice,
which were rescued by cardiomyocyte-specific NOS3 overexpression. Data are mean 6 SEM from 6–7 mice per group. *P,0.01 vs. all other groups. +/
+, WT; 2/2, knockout; Tg, transgenic. Tg;2/2 and Tg;+/+ indicate NOSTg;NOS32/2 and NOS3Tg, respectively.
doi:10.1371/journal.pone.0077611.g002

Materials and Methods

Three-Dimensional Reconstructions and Histological
Analysis

Animals

Three-dimensional (3D) reconstructions of the heart and AV
valves were performed using Masson’s trichrome stained serial
sections of P1 hearts through the AMIRAH software (Template
Graphics Software, USA) as previously described [20]. AV valve
volumes were determined using the AMIRAH program.

Breeding pairs of NOS32/2 (stock No. 002684) and wild-type
C57BL/6 (NOS3+/+) mice were purchased from Jackson Laboratory (Bar Harbor, Maine). A breeding program was carried out
to produce neonates. Genotyping of NOS32/2 and NOS3+/+
mice was performed by a polymerase chain reaction (PCR)
method using genomic DNA prepared from tail biopsies. A timed
breeding program was carried out. Vaginal plugging was
monitored in the morning of each day and when plugged, was
considered 0.5 days into pregnancy. Embryonic hearts were
collected at E10.5, E12.5, and postnatal day 0. The investigation
conforms to the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (NIH Publication
#85-23, revised 1996) and the experimental protocols were
approved by Animal Use Subcommittee at Western University.

Heart Function Measurements
Left ventricular (LV) and right ventricular ejection fraction and
fractional shortening were measured using the Vevo 2100
ultrasound imaging system (Visual Sonics, Canada) [20]. Briefly,
2-dimensional images of the heart were obtained in short-axis view
using a dynamically focused 40 MHz probe. The M-mode cursor
was positioned perpendicular to the LV anterior and posterior
walls. The LV internal end-diastolic dimension (LVIDd) and LV
internal systolic dimension (LVIDs) were measured from M-mode
recordings. LV ejection fraction was calculated as: EF
(%) = [(LVIDd)32(LVIDs)3]/(LVIDd)36100. Fractional shortening was calculated as: FS (%) = (LVIDd2LVIDs)/LVIDd6100.
The M-mode measurements of the left ventricular ejection fraction
and fractional shortening were averaged from 3 cycles. Both left
and right atrial areas were traced and calculated under the apical
4-chamber view in B-mode. AV valve E/A ratio, regurgitation and
flow pattern were measured through both color flow Doppler
recordings and pulsed-wave Doppler echocardiograms [42].

Generation of Human NOS3 Transgenic Mice
A new line of cardiac-specific mice overexpressing human
isoforms of NOS3 (NOS3Tg) was generated [20]. Briefly, human
NOS3 complementary DNA was inserted into the b-myosin heavy
chain promoter expression vector [39] to permit the expression of
human NOS3 only during embryonic development and specifically in the heart. Our previous studies have shown that the
transgene is specifically expressed in the heart during embryonic
development [20]. Genotypes were identified by PCR using
genomic DNA from tail biopsies.

Ex vivo Heart Cultures
E12.5 NOS3+/+ and NOS32/2 hearts were explanted and
cultured in M199 medium (Sigma-Aldrich, USA) supplemented
with 10% FBS as previous described [20]. Hearts were stabilized
for 2 hours prior to any treatment. NOS3+/+ and NOS32/2
hearts were beating throughout the entirety of the experiment.
NOS3+/+ and NOS32/2 hearts were treated with 100 mM 1H[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ) (Sigma-Aldrich,
USA) and 2 mM 8-Bromo-cGMP (Sigma-Aldrich, USA), respectively for 6 hours. Some NOS3+/+ and NOS32/2 hearts were
treated with recombinant TGFb protein (10 ng/ml) for 18 hours.
Hearts were then collected and mRNA levels of Snail1, TGFb and
BMP2 were analyzed by real time RT-PCR.

General Tissue Processing
Neonatal NOS3+/+, NOS32/2, NOS3Tg/NOS32/2 and
NOS3Tg mice were used for analysis. Hearts were isolated and
fixed in 4% paraformaldehyde, dehydrated, and embedded in
paraffin. Five micro-meter transverse serial sections were mounted
onto albumin/glycerin coated glass slides.

Immunohistochemistry and Immunofluorescence
Established protocols were used with minor modifications
[18,20,40]. Briefly, after deparaffination and rehydration of the
slides, microwave antigen retrieval was applied by heating them
for 10 min at 98uC in a citric acid buffer (0.01 M in aqua-dest,
pH 6.0). Inhibition of endogenous peroxidase was performed with
a solution of 0.3% H2O2 in phosphate buffered saline (PBS) for
30 min. The slides were incubated overnight with either 1:500
anti-Snail1 (Abcam, USA). Next, the goat anti-rabbit secondary
antibody conjugated with biotin (1:200, Vector Laboratories,
USA) was added for 60 min in PBS. Subsequently, slides were
incubated with ABC reagent (Vector Laboratories, USA) for
30 min. For visualization, the slides were incubated with 400 mg/
ml 3–39di-aminobenzidin tetrahydrochloride (Sigma-Aldrich,
USA) and 100 mL of 30% H2O2 dissolved in PBS for 10–
15 min. Counterstaining was performed with 0.1% hematoxylin.
The size and length of AV valves were measured at the proximal
(hinge) and distal aspects of the leaflets as described previously
[41].

Real-time RT-PCR
Standard protocol was used as previous described [7,18,20,40].
Briefly, total RNA was isolated from cultured fetal hearts with a
RNA isolation kit (Qiagen, Canada). cDNA was synthesized using
M-MLV (Invitrogen, Canada) reverse transcriptase and random
primers (Invitrogen, Canada). Real-time PCR was conducted
using SYBR Green PCR Master Mix as per manufacturer’s
instructions (Eurogentec, USA). The oligonucleotide primers used
in this study are summarized in Table S1. Samples were amplified
for 35 cycles using Eppendorf Real-Time PCR machine and
analyzed using cycle threshold (Ct) analysis. The expression levels
of Snail1, BMP2 and TGFb in relation to 28S rRNA were
determined using a comparative Ct method [40].

Measurement of cGMP
The cGMP levels in the heart were measured using an ELISA
kit according to the manufacturer’s instructions (ADI-900-014,
PLOS ONE | www.plosone.org
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Figure 3. Regurgitation of tricuspid valve in NOS32/2 mice at P0. Backflow of tricuspid valves was determined by color (A) and pulsed-wave
(B) Doppler echocardiography. Backflow during systole is indicated by arrows. WT mice had minor backflow in tricuspid valves. However, NOS32/2
mice showed marked tricuspid valve backflow. (C–D) Quantification of tricuspid valve regurgitation. Significant regurgitation was observed in
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NOS32/2 mice, which were rescued by cardiomyocyte-specific NOS3 overexpression. Data are mean 6 SEM from 6–7 mice per group. *P,0.01 vs. WT
(NOS3+/+), {P,0.01 vs. NOS32/2. +/+, WT; 2/2, knockout; Tg, transgenic. Tg;2/2 and Tg;+/+ indicate NOSTg;NOS32/2 and NOS3Tg, respectively.
doi:10.1371/journal.pone.0077611.g003

Figure 4. Cardiac function determined using echocardiography at P0. (A–D) Both left and right ventricular ejection fraction and fractional
shortening were significantly decreased in the NOS32/2 mice compared with WT controls, which were rescued by cardiomyocyte-specific NOS3
overexpression. (E–F) E/A ratio showed no significant difference between all groups. (G–H) Left and right atrial size was significantly increased in
NOS32/2 mice compared with WT controls, which was rescued by cardiomyocyte-specific NOS3 overexpression. Data are mean 6 SEM from 6–7 mice
per group. *P,0.05 vs. WT (NOS3+/+), {P,0.05 vs. NOS32/2. +/+, WT; 2/2, knockout; Tg, transgenic. Tg;2/2 and Tg;+/+ indicate NOSTg;NOS32/2 and
NOS3Tg, respectively.
doi:10.1371/journal.pone.0077611.g004
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Figure 5. EndMT is impaired in the AV cushion of NOS32/2 hearts at E12.5. (A) 3D reconstructions (Left and middle columns, Red for Snail1+
cells; Grey for cushion) and representative Snail1 immunostaining (Right column, Brown staining indicates Snail1+ cells). Scale bar = 50 mm. (B)
Quantification of Snail+ mesenchymal cell volume from 3D reconstructed in E12.5 AV cushions. (C) Total number of mesenchymal cells (Snail positive
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and negative cells) in E12.5 cushions was quantified. (D) Quantification of endocardial cushion size at E12.5 from 3D reconstructions. (E)
Quantification of Snail1+ endocardial cushion mesenchymal cells at E10.5 from 3D reconstructions. (F) Quantification of total endocardial cushion
mesenchymal cells at E10.5. (G) Quantification of endocardial cushion size at E10.5 from 3D reconstructions. N = 3–4 mice per group. *P,0.05 vs.
WT(NOS3+/+) or WT control. {P,0.05 vs. NOS32/2.
doi:10.1371/journal.pone.0077611.g005

Enzo Life Sciences, USA) [43]. Neonatal NOS3+/+, NOS32/2,
NOS3Tg/NOS32/2 and NOS3Tg hearts were used for analysis.
Briefly, 10 mg of protein lysates from the isolated hearts and
standards were added to the cGMP conjugated to alkaline
phosphatase and an anti-cGMP antibody, and incubated for 2
hours at room temperature. This incubation allows the antibody to
bind the cGMP in the sample or conjugate in a competitive
manner. After 3 washes, p-nitrophenyl phosphate (pNpp)
substrates were added and the plated and incubated for 1 hour
at room temperature. This incubation allows the catalysis of pNpp
substrate by the alkaline phosphatase on the cGMP conjugate.

The reaction was then stopped by tri-sodium phosphate solution
and the optical density was read at 405 nm. The amount of signal
is indirectly proportional to the amount of cGMP in the sample.

Endocardial Cushion Explant Culture
Endocardial cushion explants were cultured accordingly to
methods previously described with minor modifications [32].
Briefly, E10.5 NOS3+/+ and NOS32/2 hearts were planted on a
35 mm petri dish coated with 1 mg/ml collagen type I gel
overnight for attachment. After attachment, the hearts were
treated with 100 ml of M199 supplemented with 10% FBS and

Figure 6. cGMP regulates expression of Snail1, TGFb and BMP2 in E12.5 hearts. (A) cGMP levels in P0 hearts. (B–D) E12.5 ex vivo heart
cultures. Cultured WT and NOS32/2 hearts were treated with ODQ (100 mM), a soluble guanylate cyclase inhibitor, or 8-Br-cGMP (2 mM), a cGMP
analog for 6 hrs. Snail1, TGFb and BMP2 mRNA levels were determined by real-time RT-PCR. (E) E12.5 ex vivo heart cultures from WT and NOS32/2
mice were treated with recombinant TGFb protein (10 ng/ml). TGFb mRNA levels were determined by real-time RT-PCR. N = 6 hearts per group for C–
G. *P,0.05 vs. WT(NOS3+/+) or WT control. {P,0.05 vs. NOS32/2 or NOS32/2 control.
doi:10.1371/journal.pone.0077611.g006
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Figure 7. Atrioventricular (AV) endocardial cushion explant culture from E10.5 NOS32/2 and WT mice. (A) Spindle shaped
mesenchymal cells (arrows) were formed after 24 hours of culture. Lower panel is an enlargement of the boxed area. (B) The total number of
mesenchymal cells per mm of explant cushion tissue was significantly decreased in NOS32/2 compared to WT explants. Data are mean 6 SEM from 6
explants per group. *P,0.05 vs. WT(NOS3+/+). Black scale bar = 100 mm, white scale bar = 10 mm. (C) Proposed signaling pathway by which NOS3
promotes endocardial EndMT and AV valve development.
doi:10.1371/journal.pone.0077611.g007

allowed 2 days for EndMT to occur. After 2 days, these hearts
were imaged under phase contrast microscopy (Observer D1,
Zeiss, Germany). The number of spindle-like mesenchymal cells
was counted.

Supporting Information
Figure S1 Three-dimensional (3D) reconstructions of mitral
valve of WT, NOS32/2, NOS3Tg and NOS3Tg;NOS32/2 mice
at P0 (A–D). 3D reconstructions were made by putting together
images taken from approximately 100 serial heart sections at 5 mm
using Amira software. Valve locations in the heart are shown.
Whole heart images are frontal views of the heart. Isolated valve
images are viewed from the left atrium into the left ventricle. E.
Quantitative analysis of mitral valve volume. Data are mean 6
SEM from 5 mice per group. F. Quantification of mitral valve
length in P0 hearts. G. Quantification of mitral valve cell density
in P0 hearts. *P,0.01 vs. WT. {P,0.01 vs. NOS32/2 mice.

Statistical Analysis
Data are presented as mean 6 SEM. Unpaired Student’s t test
was used for 2 group comparisons. One way ANOVA followed by
Student-Newman-Keuls test was performed for multi-group
comparisons. P,0.05 was considered statistically significant.
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Tg;2/2 and Tg;+/+ indicate NOSTg;NOS32/2 and NOS3Tg,
respectively.
(TIF)

Figure S3 Mitral and tricuspid valve length measurements at
E15.5. A. Length of anterior and posterior leaflets of the mitral
valve. B. Length of anterior and posterior leaflets of the tricuspid
valve. Data are mean 6 SEM from 5 mice per group. *P,0.05 vs.
WT. {P,0.05 vs. NOS32/2 mice. Tg;2/2 and Tg;+/+ indicate
NOSTg;NOS32/2 and NOS3Tg, respectively.
(TIF)

Figure S2 3D reconstructions of tricuspid valve of WT,
NOS32/2, NOS3Tg and NOS3Tg;NOS32/2 mice at P0 (A–D).
3D reconstructions were made by putting together images taken
from approximately 100 serial heart sections at 5 mm using Amira
software. Valve locations in the heart are shown. Whole heart
images are frontal views of the heart. Isolated valve images are
viewed from the right atrium into the right ventricle. E.
Quantitative analysis of tricuspid valve volume. F. Quantification
of tricuspid valve length in P0 hearts. G. Quantification of
tricuspid valve cell density in P0 hearts. Data are mean 6 SEM
from 5 mice per group. *P,0.01 vs. WT. {P,0.01 vs. NOS32/2
mice. Tg;2/2 and Tg;+/+ indicate NOSTg;NOS32/2 and
NOS3Tg, respectively.
(TIF)

Table S1 Gene name, accession number and primers

used.
(DOC)
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